A new study conducted by researchers at Kaiser Permanente has found that a considerable number of working-age adults who survive cancer and its toxic treatments, end up with substantial medical debts or declare bankruptcy.
A new study conducted by researchers at Kaiser Permanente has found that a considerable number of working-age adults who survive cancer and its toxic treatments, end up with substantial medical debts or declare bankruptcy.
The collaborative study, which also included researchers at the National Cancer Institute, CDC, Emory University, and the LIVESTRONG Foundation, analyzed data on 4719 cancer survivors between the ages of 18 and 64 years. The data was part of the LIVESTRONG 2012 survey, which was developed by the LIVESTRONG Foundation to improve the understanding on some of the practical issues and concerns of cancer survivors. In addition to their experience with finances and insurance coverage, survivors answered questions about survivorship care plans and fertility.
For the present study published in the current issue of the journal Health Affairs, the authors analyzed data on about 75% of the parent cohort and found that one-third of these survivors had gone into debt and 3% had filed for bankruptcy following their cancer treatment. More than half of those in debt owed at least $10,000. Additionally, the study found that younger survivors (who were probably yet to establish a career and earn a steady income), those with lower incomes, and those with public health insurance were at a greater risk of going into debt or filing for bankruptcy, compared with older, high income bracket, or privately insured survivors, respectively.
Based on their 2012 survey, LIVESTRONG released a brief documenting the following statistics:
In an interview with The American Journal of Managed Care, Yousuf Zafar, MD, MHS, a health policy researcher at Duke Cancer Institute who has been credited for coining the term “financial toxicity,” explained that physicians can play an important role in this process. “One simple question could save some patients a lot of money. Just asking patients ‘Do you have prescription drug coverage?’ that’s a first, very simple step to integrating costs into the medical treatment decision making.”
The lead author of the study, Matthew Banegas, PhD, MPH, at Kaiser Permanente Center for Health Research, told NBC News that cancer patients can also lose time at work. If they have to take time off, they may have to use extended time or extended leave which could impact insurance coverage and impact how cost affects them.” Indeed a study recently published in JAMA found that cancer patients who cannot avail of paid sick leave face significant financial strains.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More